Hutchmed China Ltd (13.HK/HCM.US) - High Growth Is Expected from 2024 to 2026
⬆ $Hutchmed China Ltd(00013)$ - HUTCHMED will enter a period of accelerated growth in product revenue based on major catalysts in 2024 to 2026. Global sales of fruquintinib will be the main driving force. Breakeven is drawing near. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/hutchmed-china-ltd-13-hk-hcm-us-high-growth-is-expected-from-2024-to-2026?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On Hutchmed China Ltd (00013):- https://www.smartkarma.com/entities/hutchmed-china-ltd?utm_source=tiger_community
⬆ $Hutchmed China Ltd(00013)$ - Including US$312mn upfront and milestone payments from Takeda, HCM’s consolidated revenues from oncology/immunology reached US$529mn in FY23 Continue reading on Smartkarma:- https://www.smartkarma.com/insights/hutchmed-13-hk-a-fruitful-2024-on-the-way?utm_source=tiger_community By CMB International, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cmb-international?utm_source=tiger_community On Hutchmed China Ltd (00013):- https://www.smartkarma.com/entities/hutchmed-china-ltd?utm_source=tiger_community